A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
| 대상 질환 | Inherited Mitochondrial Disease |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | PTC Therapeutics |
| 상태 | 완료 |
| 참여자 수 | 101 명 |
| 중재(약물) | Vatiquinone |
| 시작일 | 2022년 6월 22일 |
| 완료일 | 2025년 4월 15일 |
| 결과 공개일 | 2025년 12월 22일 |
요약
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
| Vatiquinone | 91 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner